menu
    • menu
    [{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eckert & Ziegler Strahlen \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Eckert & Ziegler Strahlen \/ Point Biopharma"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eckert & Ziegler Strahlen \/ Eckert & Ziegler Strahlen","highestDevelopmentStatusID":"7","companyTruncated":"Eckert & Ziegler Strahlen \/ Eckert & Ziegler Strahlen"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eckert & Ziegler Strahlen \/ Eckert & Ziegler Strahlen","highestDevelopmentStatusID":"10","companyTruncated":"Eckert & Ziegler Strahlen \/ Eckert & Ziegler Strahlen"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"68-Ga DOTA-TATE","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eckert & Ziegler Strahlen \/ Eckert & Ziegler Strahlen","highestDevelopmentStatusID":"10","companyTruncated":"Eckert & Ziegler Strahlen \/ Eckert & Ziegler Strahlen"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Agreement","leadProduct":"177Lu-Satoreotide Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2024","type":"Partnership","leadProduct":"225-Ac PSMA-RADmAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Eckert & Ziegler Strahlen

    Menu

    Eckert & Ziegler Strahlen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ac-225 Lintuzumab,Spironolactone,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Actinium pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Actinium & Eckert-Ziegler Ink Ac-225 Supply Deal for Development Activities

                            Details : Under the agreement, Actinium will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A (Ac-225 Lintuzumab) for AML.

                            Product Name : Actimab-A

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 24, 2025

                            Lead Product(s) : Ac-225 Lintuzumab,Spironolactone,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Actinium pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-Satoreotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Ariceum Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ariceum, Eckert Sign Agreement for Radiotherapeutics Cancer Treatments

                            Details : Eckert & Ziegler will supply Ariceum with n.c.a. Ac-225 and Lu-177 used to radiolabel Ariceum's proprietary lead radiopharmaceutical drug SS0110 (satoreotide) targeting hard-to-treat cancers.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            December 05, 2024

                            Lead Product(s) : 177Lu-Satoreotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Ariceum Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac PSMA-RADmAb

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

                            Details : The partnership aims to provide Telix with both an additional commercial source of 225Ac and access to a platform technology for use in the development of next generation TATs, including TLX592.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : 225-Ac PSMA-RADmAb

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga DOTA-TATE

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Hea...

                            Details : 68-Ga DOTA-TATE is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 05, 2024

                            Lead Product(s) : 68-Ga DOTA-TATE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PNT2001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

                            Details : Under the agreement, Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands, including PSMA-targeted PNT2001 program.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            April 04, 2023

                            Lead Product(s) : PNT2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Rosopatamab Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Telix Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement

                            Details : This agreement further enhances Telix’s existing 177Lu supplier network, by immediately commence supply for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuxima...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            February 09, 2022

                            Lead Product(s) : 177-Lu Rosopatamab Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Telix Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth